Zimmer Biomet Holdings, Inc. (ZBH)

Zimmer Biomet Holdings, Inc.'s Q·Score is 6.9/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. Earnings growing 34% year-over-year on 9% revenue growth. Key area to monitor: cautious analyst consensus — few Buy ratings. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for ZBH is $98.52, based on ratings from 21 Wall Street analysts. This is 18.8% above the current price of $82.90. Price targets are forward-looking estimates and not guarantees of future performance.

Zimmer Biomet Holdings, Inc. (ZBH) scores favorably on valuation metrics relative to sector peers and analyst targets. Its forward P/E ratio stands at 9.2×. The consensus analyst price target of $98.52 is 19% above the current price.

Zimmer Biomet Holdings, Inc. has a net profit margin of 9.1%, which is positive but relatively thin. Its gross margin stands at 70.2%, indicating a high-margin business model.

Zimmer Biomet Holdings, Inc. currently offers a dividend yield of 1.16%, a modest payout typical for growth-oriented companies. Dividend yields can change based on price movements and company payout decisions.

Zimmer Biomet Holdings, Inc. is reporting modest revenue growth of 9.3%. Earnings are also growing at 34.1%, indicating improving profitability.

Zimmer Biomet Holdings, Inc. has a debt-to-equity ratio of 0.60×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 1.73×, indicating comfortable short-term liquidity.